CytomX and Regeneron Expand Collaboration on Tumor-Activated Bispecific Cancer Therapies

CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their 2022 strategic collaboration to develop conditionally activated bispecific cancer immunotherapies that combine CytomX's Probody masking platform with Regeneron's Veloci-Bi bispecific antibody (bsAb) technology. Under the expanded agreement, CytomX will receive a $37 million target selection payment for two additional nominated programs, with Regeneron retaining options to select up to six further targets. Total potential target nomination, preclinical, clinical, regulatory, and commercial milestone payments across the expanded collaboration could reach approximately $4 billion, with CytomX also eligible for tiered global net sales royalties.¹

"Our ongoing research collaboration with Regeneron is based on a shared commitment to cutting-edge science and a vision to push the boundaries of cancer immunotherapy," said Sean McCarthy, DPhil, CEO and chairman of CytomX, in a company press release.¹ "Regeneron's deep expertise in bispecific immunotherapies has made them an ideal partner in expanding the reach of the [Probody} platform."

What is the scientific rationale for combining conditional activation with bsAb technology in oncology?

T-cell–engaging bsAbs have demonstrated clinical activity across hematologic malignancies, but their application in solid tumors has been constrained by on-target, off-tumor toxicity, which is a consequence of target antigen expression on normal tissues in addition to tumor cells.² CytomX's Probody platform addresses this limitation through protease-activated masking, in which the therapeutic antibody is rendered inactive in systemic circulation by a masking domain that is cleaved selectively by proteases enriched in the tumor microenvironment, such as matrix metalloproteinases and urokinase plasminogen activator.³

This conditional activation strategy is designed to widen the therapeutic window by concentrating antibody activity at the tumor site. This approach could potentially enable targeting of antigens previously considered undruggable due to normal tissue expression. Combined with Regeneron's Veloci-Bi bispecific format, the approach aims to produce T-cell engagers with improved selectivity profiles.^1,3

What are the financial terms and operational responsibilities under the expanded agreement?

Under the expanded agreement, Regeneron is responsible for funding all preclinical and clinical development and commercialization activities across collaboration programs. The $37 million payment to CytomX covers two newly selected targets. Regeneron holds options on up to six additional future targets, with each nomination triggering further payments.

The approximately $4 billion milestone figure represents aggregate potential across the full expanded scope, encompassing all nominated targets and multiple indications and commercial territories. This financial structure reflects a theoretical maximum contingent on sustained clinical and commercial success across multiple programs rather than near-term value, which is representative of most tiered milestone frameworks in platform collaborations.

What is the clinical and competitive context for tumor microenvironment–activated cancer therapies?

Conditional activation strategies represent one of several approaches under investigation to improve the selectivity of cancer immunotherapies, alongside antibody-drug conjugates (ADCs) with tumor-selective linker chemistry, pH-sensitive antibodies, and synthetic biology–based logic-gated cell therapies.⁴ CytomX's clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051), a masked epithelial cell adhesion molecule-directed ADC armed with a topoisomerase I inhibitor payload in development for metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine in development for metastatic melanoma. Neither the collaboration targets announced in this expanded deal nor clinical-stage data from the Regeneron partnership programs were disclosed. CytomX has established additional platform collaborations with Amgen and Moderna.¹

What limitations apply and what data disclosures would advance understanding of the platform's clinical potential?

The collaboration targets selected under the expansion have not been disclosed, which preclude assessment of their clinical rationale or competitive differentiation. The companies have also not disclosed investigational new drug application filings, trial initiation timelines, or preclinical data packages for the new programs in this announcement.

Peer-reviewed clinical data from the CytomX–Regeneron collaboration programs are not yet available in public literature. Meaningful evaluation of the platform's clinical utility in solid tumors will require phase 1 data from conditionally activated bispecific programs, including pharmacodynamic evidence of tumor-selective activation and preliminary efficacy signals.

References

1. CytomX Therapeutics. CytomX announces expansion of strategic research collaboration with Regeneron in the field of conditional bispecific therapeutics for the treatment of cancer. Published June 3, 2026. Accessed June 4, 2026. https://ir.cytomx.com/news-releases/news-release-details/cytomx-announces-expansion-strategic-research-collaboration
2. Goebeler ME, Bargou RC. T cell-engaging therapies—BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418-434. doi:10.1038/s41571-020-0347-5
3. Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5(207):207ra144. doi:10.1126/scitranslmed.3006682
4. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. doi:10.1038/s41392-022-00947-7